160 related articles for article (PubMed ID: 29854306)
1. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
2. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
[TBL] [Abstract][Full Text] [Related]
3. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
4. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
[TBL] [Abstract][Full Text] [Related]
5. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
[TBL] [Abstract][Full Text] [Related]
6. The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.
Stafman LL; Waldrop MG; Williams AP; Aye JM; Stewart JE; Mroczek-Musulman E; Yoon KJ; Whelan K; Beierle EA
J Pediatr Surg; 2019 Jun; 54(6):1206-1213. PubMed ID: 30898394
[TBL] [Abstract][Full Text] [Related]
7. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
[TBL] [Abstract][Full Text] [Related]
9. PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
Stafman LL; Williams AP; Marayati R; Aye JM; Stewart JE; Mroczek-Musulman E; Beierle EA
PLoS One; 2019; 14(4):e0214469. PubMed ID: 30969990
[TBL] [Abstract][Full Text] [Related]
10. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
Cervantes-Gomez F; Stellrecht CM; Ayres ML; Keating MJ; Wierda WG; Gandhi V
Oncotarget; 2019 Apr; 10(29):2793-2809. PubMed ID: 31073371
[TBL] [Abstract][Full Text] [Related]
11. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.
Julson JR; Quinn CH; Bownes LV; Hutchins SC; Stewart JE; Aye J; Yoon KJ; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1155-1163. PubMed ID: 36907773
[TBL] [Abstract][Full Text] [Related]
13. PIM Kinases in Multiple Myeloma.
Wu J; Chu E; Kang Y
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503111
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
[TBL] [Abstract][Full Text] [Related]
15. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
16. Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Doshi KA; Trotta R; Natarajan K; Rassool FV; Tron AE; Huszar D; Perrotti D; Baer MR
Oncotarget; 2016 Jul; 7(30):48280-48295. PubMed ID: 27374090
[TBL] [Abstract][Full Text] [Related]
17. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma.
Bownes LV; Julson JR; Quinn CH; Hutchins SC; Erwin MH; Markert HR; Stewart JE; Mroczek-Musulman E; Aye J; Yoon KJ; Ohlmeyer M; Beierle EA
J Pediatr Surg; 2023 Jun; 58(6):1145-1154. PubMed ID: 36907775
[TBL] [Abstract][Full Text] [Related]
19. PIM Kinase as an Executional Target in Cancer.
Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
[TBL] [Abstract][Full Text] [Related]
20. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
